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Summary Piritrexim is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit
dihydrofolate reductase. We performed a multicentre phase II study with piritrexim in patients with locally
advanced or metastatic breast cancer. Twenty-four patients of which sixteen had received prior chemotherapy,
were initially treated with 25 mg piritrexim orally administered trice daily for four days, repeated weekly, with
provision for dose escalation or reduction according to observed toxicity. Of twenty-one patients evaluable for
tumour response, one patient achieved a partial response which lasted for 24 weeks. Three patients had stable
disease during 12 weeks of treatment, seventeen had progressive disease. Piritrexim was generally well
tolerated, in eighteen patients the dose could be escalated. Myelotoxicity was the most frequent observed
toxicity of this piritrexim regimen. Leucopenia and thrombocytopenia grade 3/4 occurred in 38% of the
patients sometime during treatment. Pharmacokinetic analysis of piritrexim in three patients during the first
treatment cycle, revelaed peak levels 1 to 2 h after an oral dose, with a trend towards a higher peak plasma
levels and AUCs on the fourth dosing day compared with the first dosing day. In conclusion, orally
administered piritrexim appears to be a regimen with little activity in patients with locally advanced or
metastatic breast carcinoma.
Piritrexim (2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-
pyridol[2,3-d]pyrimidine; BW301U) is a lipid-soluble
antifolate which, like methotrexate, has a potent capacity to
inhibit dihydrofolate reductase (Sedwick et al., 1982; Sigel et
al., 1987). There are, however, several differences between
piritrexim and methotrexate. Piritrexim (PTX) is more
lipophylic, enters cells rapidly and is not polyglutamated
intracellularly, in contrast to methotrexate (Duch et al.,
1982). In the human tumour cell cloning assay the
antitumour activity of piritrexim was found to be favourable
when compared with methotrexate in lung, ovary, colon, and
breast cancer (Marshall et al., 1985; Neuenfeldt et al., 1982).
Piritrexim was also capable of inhibiting the growth of
several types of MTX resistant cells (Sedwick et al.,
1982).
Intravenous administration caused severe peripheral vein
phlebitis (Weiss et al., 1989), and for this reason more atten-
tion was paid to the oral route. Tumour responses have been
observed in phase II studies in melanoma, non-small cell lung
carcinoma, bladder carcinoma, and head and neck cancer
(Feun et al., 1991; Kris et al., 1987; De Wit et al., 1993; Uen
et al., 1992).
Methotrexate is effective as a single agent in metastatic
breast cancer (Carter, 1976), and many patients currently
receive methotrexate in first line combination therapy.
Therefore, treatment with piritrexim, which could potentially
also circumvent methotrexate resistance, could be of value in
patients previously treated for breast carcinoma.
We therefore performed a multicenter phase II study with
oral piritrexim in patients with locally advanced or metastatic
breast cancer. The regimen was designed to entail the optimal
dose for individual patients. In a limited number of patients
PTX pharmacokinetics were evaluated on days one and four.
Patients and methods
Patients
To be eligible for this study, patients were required to have
histologically confirmed breast cancer with measurable local
or metastatic disease not amenable to local therapy. They
also had to fulfill the following criteria: (a) female sex; (b)
age above 18 years; (c) an estimated life expectancy of > 12
weeks; (d) a WHO performance status of <2; (e) complete
recovery from all toxic effects arising from prior treatments
which consisted of either one or two different chemotherapy
regimens, with or without hormonal treatment, or at least
one course of hormonal treatment; (f) a treatment free inter-
val of at least 4 weeks; (g) a minimum of 4 weeks elapsed
since radiotherapy; (h) leukocyte count >4 x I091' and
platelet count > 100 x I0 1'; (i) serum creatinine level
<1401tmol 1'; (j) serum bilirubin <25ymol 1'. This pro-
tocol was approved by the Medical Ethical Committees of
both the University Hospital Groningen, the Netherlands,
and King's College Hospital, London, United Kingdom.
Consent was obtained from all patients after being informed
of the investigational nature of this treatment.
Study design
PTX (provided by Wellcome, Beckenham, UK) was
administered orally at an initial dose of 25 mg three times
daily for four days, repeated weekly (one cycle; 300 mg/
week). Doses were equally spaced and taken at least 1 h
before or 2 h after meals, to ensure adequate absorption.
Dose escalations were provided if no toxicity was
encountered after a set of two cycles (for the first eight
patients after a set of four cycles). First escalation: 25 mg
three times daily for five days (375 mg/week); Second escala-
tion: 25 mg four times daily for 5 days (500 mg/week). The
dose was unchanged if grade 1 myelotoxicity had been
experienced in a set of two cycles. There was a discontinua-
tion of treatment in the case of WHO grade 2 myelotoxicity
within the first 2 weeks (for the first eight patients within 3
weeks), and grade 3 or 4 at any time. After recovery, treat-
ment was resumed with 25 mg three times daily for 3 days
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(first reduction; 225 mg/week), with provision for a second
reduction to 25 mg twice daily for 3 days (first reduction;
225 mg/week), with provision for a second reduction to
25 mg twice daily for 3 days (150 mg/week). Patients were
assessed weekly at the outpatient clinic to document toxicity
(scored according to WHO criteria), and to make dose
adjustments if necessary.
To be evaluable for response a patient had to receive at
least four cycles of PTX. Tumour evaluations were per-
formed, according to standard criteria, at entry and after
every four cycles. In case of a tumour response, patients
continued therapy until progression. Patients with SD at 12
weeks, continuation of the treatment was offered for another
4 weeks. In case of PD, patients were taken off study.
In three patients pharmacokinetic analysis was performed
on the first and fourth day, i.e. the first and last dose, of the
first cycle of PTX. Blood samples were obtained prior to an
oral dose (25 mg) and then at 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h
after the dose. The blood samples were collected in
heparinised tubes and placed on ice until the plasma was
separated by centrifugation. Plasma samples were stored
frozen at - 20C until assayed. PTX was extracted from
plasma by adding acetronitrile (2:1 containing internal stan-
dard Ro 31-0644 at 0.2 Lg ml-'). The mixture was vortexed
for 10s and centrifuged (8000g for 5 min), the supernatant
was evaporated to dryness and the residue was resuspended
in running buffer. The concentration of PTX was determined
as previously described (Dennis, 1990). In short, the
measurements were performed by reversed phase high liquid
performance chromatography using a Waters C18 yBondPak
10 cm x 8 mm radial packed column. Separations were
achieved by eluting with a linear gradient of 14% to 33%
acetronitrile in a 1% acetic acid solution over 15 min at a
flow rate of 3 ml min-'. Detection was performed at 320 nm
and identification was performed by chromatographic and
spectral properties using a Waters photodiode array detec-
tor.
Pharmacokinetic parameters were determined by model-
independent methods. The AUC from time 0 to 6 h was
derived by the trapezoidal method. The AUC from 0 to 6 h
measured at steady state is presumed to be equivalent to the
AUC extrapolated to infinity following a single dose (Gibaldi
& Perrier, 1982).
Results
Twenty-four patients were entered into this trial. The charac-
teristics of these patients are outlined in Table I. In Figure 1
the number of cycles with initial PTX dose as well as with
PTX dose escalation or de-escalation is shown. All patients
Table I Patient characteristics
Number
Patients entered
Age median (yrs)
Range
WHO performance status
0
1
2
Prior treatment
Surgery
Radiotherapy
Chemotherapy
Hormonal
Sites of disease
Primary/local
Lymph nodes
Lung
Liver
Bone
Other
24
66
(35- 84)
4
13
7
16
18
16
23
14
12
10
4
9
2
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Figure I Number of administered cycles of PTX at a certain
dose level.
were considered to be evaluable for toxicity. Three patients
completed less than four cycles of PTX: one patient
developed a grade 3 leucopenia, patient a grade 4 throm-
bocytopenia during the first week of PTX, and both were
taken off study: A third patient stopped PTX after two cycles
due to tumour progression. Therefore, 21 patients were
evaluable for response.
One patient achieved a partial response lasting for 24
weeks. This response in lymph nodes occurred after 12 weeks
of treatment. Three patients had SD at 12 weeks, one of
them was kept on PTX for 16 weeks. These four patients all
had received previous chemotherapy. Seventeen patients had
progressive disease.
Toxicity
The total number of treatment weeks was 200, median 7
(range 1-36). In 18 patients the dose was escalated by one
step, in nine it could be escalated by two steps. In three
patients the dose had to be de-escalated by one step (Figure
1). The observed toxicity is summarised in Table II.
Myelotoxicity was the most frequently observed toxicity.
Leucopenia and thrombocytopenia grade 3/4 occurred in
38% of the patients sometime during treatment. It was of
short duration with recovery usually occurring within a few
days after treatment interruption, and never lasted for more
than one week. There were no episodes of neutropenic fever
or signs of clinical bleeding. In several patients grade 3/4
myelotoxicity developed within the first treatment week. In
three patients treated for 12 weeks or more, a red blood cell
transfusion was necessary because of symptomatic anaemia.
There was no clear evidence that patients who received exten-
sive previous chemotherapy and/or radiotherapy experienced
more haematological toxicity than patients without extensive
prior therapy, since two of the four patients who received no
prior myelotoxic treatment experienced a grade 4 throm-
bocytopenia. Mild nausea and vomiting occurred in 33% of
the patients, anti-emetic treatment (metoclopramide) was
required in only a minority. In four patients a maculo
papular rash developed during PTX, while grade 1 mucositis
was seen in three patients.
Pharmacokinetics
The concentration time curves on day 1 and 4 of the first
PTX cycle of three patients are shown in Figure 2. Phar-
macokinetic parameters are listed in Table III. PTX was
rapidly absorbed, with the peak levels occurring 1 to 2 h after
an oral dose. The peak plasma level, AUC, and half-life on
the fourth dosing day seemed to be somewhat higher than on
the first, although the range was wide.
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Table II Most pronounced toxicity (WHO grade) observed during
PTX treatment
WHO grade
0 1 2 3 4
Leukocytes 5 10 5 4 0
Thrombocytes 12 3 3 2 4
Haemoglobin 8 12 4 0 0
Nausea/vomiting 16 5 3 0 0
Skin 20 4 0 0 0
Mucositis 21 3 0 0 0
Liver 22 2 0 0 0
Renal 22 2 0 0 0
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Figure 2 PTX plasma concentration time curves of three
different patients on day 1 and day 4 of the first cycle of
PTX.
Table III Pharmacokinetic parameters of three patients
Time to peak
(h)b
2 (1.5-2)
1 (0.5-2)
aMean ± s.d. bMedian (range).
Peak levela AUCa
(ig ml-') (tg ml' h-')
0.34 ± 0.27 1.27 ± 1.04
0.81 ± 0.53 2.56 ± 1.02
Discussion
Based on its in vitro properties, PTX was considered to be an
interesting drug for patients with locally advanced or meta-
static breast cancer. This phase II study was designed to
evaluate the efficacy of orally administered PTX in a group
of previously treated patients with advanced local or meta-
static breast cancer. Our results indicate that when
administered three times daily for 4 days, repeated weekly,
PTX shows only minimal activity. One PR out of 21
evaluable patients (response rate 5% with a 95% confidence
interval 0 to 24%) was observed. This is a low response rate
when compared with single agent MTX therapy (Carter,
1976). There is a limited number of phase II studies employ-
ing repeated daily dosing with oral PTX. These studies
showed tumour responses in seven out of 31 patients with
metastatic melanoma, one out of 31 non-small cell lung
carcinoma patients, in 11 out of 29 patients with metastatic
urothelial cancer, and nine of 33 with advanced head and
neck cancer (Feun et al., 1991; Kris et al., 1987; De Wit et
al., 1993; Uen et al., 1992). These data suggest that for
melanoma and urothelial cancer PTX might be superior to
that of the mother compound methotrexate. However, this
does not seem to be the case for breast cancer. It has been
suggested that the superior effect of PTX compared with
methotrexate could be due to differences in tissue distribution
of the two drugs, with high PTX levels being seen in the skin
and lung of the rat (Sigel et al., 1987).
In the present study PTX was generally well tolerated. The
dose limiting toxicity was myelosuppression, especially
thrombocytopenia. The onset of thrombocytopenia was
rather suddenly, it sometimes occurred already after only one
treatment course; while other patients could be treated with
PTX for longer periods without signs of substantial
myelotoxicity. Just as in the other studies with orally
administered PTX, mild nausea and vomiting, skin rash and
mucositis were observed. The large variations in toxicity
experienced by different patients may well be due to varying
PTX absorption. Formulation problems for intravenous
administration and local infusion reactions have been the
major reasons for initiating studies with the potentially att-
ractive oral route. For methotrexate it is well known that, in
contrast to most drugs, continuous low dose administration
is more myelotoxic than a short term high intravenous dose.
It cannot be excluded that high dose PTX intravenously
administered might result in a better response rate.
In this study pharmacokinetics were performed after oral
administration PTX plasma levels were determined on the
first and last doses of the first cycle twice on different days.
The results obtained for the PTX half-life (range 1.04 to
6.16h) are in agreement with literature (Laszlo et al., 1987;
Adamson et al., 1990; Adamson et al., 1992). Two studies in
children with orally administered PTX revealed a half-life
between 1.1 and 4.5 h (Adamson et al., 1990; Adamson et al.,
1992). In our study, just as in the pediatric study, it was
found that PTX was rapidly absorpted with peak levels
0.5-2 h after drug administration. The PTX levels in the
children's study with a similar regimen were not determined
on a fixed day (Adamson et al., 1990; Adamson et al., 1992).
The present study is the first in which the pharmacokinetic
on two fixed days of a cycle were studied. It shows that in all
three patients the pharmacokinetics were different on day one
and four. Higher peak and AUC values were found at the
end of the cycle and the apparent elimination half-life tended
to be longer. These data may indicate a broad variability in
absorption of PTX through the cycle. In the two studies in
which bioavailability was studied it was found that the
systemic bioavailability of PTX varied by up to 50% between
patients, most probably due to differences in drug absorption
(Weiss et al., 1989; Adamson et al., 1992).
In conclusion, the administered schedule of oral PTX in
locally advanced and metastatic breast carcinoma showed a
disappointing response rate. It is possible that the variable
myelotoxicity might be a result of differences in
bioavailability, giving rise to inter- and intra-patient
variability of pharmacokinetic behaviour of PTX after oral
administration. In case of a useful application of this drug in
a certain tumour type, piritrexim plasma monitoring after
oral administration might be relevant.
Elimination
Day half-life (h)a
1 1.67±0.63
4 3.89± 2.27
t644 E.G.E. DE VRIES et al.
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